HRS Investment Holdings’s TherapeuticsMD TXMD Stock Holding History

HRS Investment Holdings’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-847	Closed	-$224K	–	96
2017 Q3	$224K	Buy	+847	New	+$245K	0.14%	85

Other funds holding TXMD

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

HRS Investment Holdings's TXMD Position: Q4 2017 in Review

HRS Investment Holdings sold out of TherapeuticsMD (TXMD) in Q4 2017, closing a stake of 847 shares — an estimated $224K sold.

HRS Investment Holdings first reported a position in TXMD in Q3 2017 and held it in 1 quarter. The position peaked at $224K in Q3 2017. 144 funds tracked by Wall St. Rank hold TXMD as of Q4 2017.

HRS Investment Holdings reported no remaining TherapeuticsMD position as of Q4 2017 after selling out during the quarter.
HRS Investment Holdings sold 847 TherapeuticsMD shares in Q4 2017, an estimated $224K.
HRS Investment Holdings first reported a position in TherapeuticsMD in Q3 2017 and held it in 1 quarter.
HRS Investment Holdings's TherapeuticsMD position peaked at $224K in Q3 2017.
144 funds tracked by Wall St. Rank held TherapeuticsMD as of Q4 2017.

Based on HRS Investment Holdings's 13F filing for Q4 2017, filed 14 Feb 2018.